Enzo: ENZ Stock Down Following Q2 Earnings, Revenues Decline Y/Y
Enzo Biochem revenues decline in second-quarter fiscal 2025. Cost cuts improve margins, but NYSE compliance issues and market slowdown persist.
Read full article »
Enzo is a New York-based biotechnology company that develops diagnostics tests for the treatment of cancer, diabetes, HIV, uveitis, and inflammatory bowel diseases.
Read more